New Treatment Approved for Malignant Ascites
The Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval for catumaxomab, marketed under the name Korjuny, to treat malignant ascites in adults when standard cancer treatments are no longer viable.
Malignant ascites is characterised by an accumulation of fluid containing cancer cells within the abdominal cavity, often necessitating procedures to drain this excess fluid. The introduction of catumaxomab offers a new treatment avenue, potentially prolonging the intervals between drainage procedures for affected patients.
Mechanism of Action
Catumaxomab is classified as a monoclonal antibody, a specific type of protein designed to bind to particular targets on cells. It specifically identifies a protein known as the epithelial cell adhesion molecule (EpCAM), which is present on the surface of certain cancer cells, including those found in ascitic fluid. By activating immune system cells, catumaxomab aids in the destruction of these cancer cells.
Julian Beach, the Interim Executive Director of Healthcare Quality and Access at the MHRA, commented on the significance of this approval, stating, “Malignant ascites can place a considerable burden on people living with cancer, particularly when further treatment options are limited. This approval provides an additional treatment option that can help extend the time patients live without needing another procedure to drain fluid from their abdomen.”
Clinical Study Insights
The primary clinical trial involved 258 patients diagnosed with malignant ascites and EpCAM-positive cancers who had exhausted chemotherapy options or were deemed unsuitable for chemotherapy. The results indicated that patients treated with catumaxomab after paracentesis—a procedure for draining abdominal fluid—did not require further drainage for approximately 46 days. In contrast, those who received only paracentesis experienced a much shorter interval of just 11 days before needing additional procedures.
Administration of catumaxomab is conducted under the supervision of a qualified medical professional experienced in oncology. The treatment involves four infusions delivered via a catheter directly into the abdominal cavity, with the dosage increasing at each session.
Possible Side Effects and Reporting Mechanism
Patients may experience common side effects, including nausea, vomiting, diarrhoea, abdominal pain, fever, chills, fatigue, and cytokine release syndrome, which is an inflammatory response triggered by immune system activation. It is essential for both healthcare professionals and patients to report any suspected side effects through the MHRA’s Yellow Card scheme.
Regulatory Details and Further Information
The marketing authorisation for catumaxomab was officially granted on 2 October to Atnahs Pharma UK Limited, under the International Recognition Procedure.
The MHRA is tasked with regulating all medicines and medical devices within the UK, ensuring their efficacy and safety. The agency operates under rigorous, evidence-based criteria to ascertain that the benefits of treatments outweigh any associated risks. As an executive agency of the Department of Health and Social Care, the MHRA is committed to the health and wellbeing of the public.

More Stories
PM Holds Key Meeting with Dutch Prime Minister Jetten on 21 November 2026
UK’s Ambitious NATO Space Launch Initiative Aims for the Stars
UK Condemns Damage to Diplomatic Premises Amid Russian Assaults on Ukraine: Key OSCE Statement